abs32.txt	the	clingen	pten	expert	panel	was	organized	by	hereditary	cancerclinical	domain	working	group	to	assemble	clinicians		researchers	and	moleculardiagnosticians	with	expertise	develop	specifications	2015	acmg/ampsequence	variant	interpretation	guidelines	for	wedescribe	finalized	pten-specific	classification	criteria	outcomesfrom	pilot	testing	of	42	variants	benign/likely	benign	(ben/lben)	pathogenic/likely	pathogenic	(path/lpath)	uncertain	significance	(vus)	andconflicting	(conf)	clinvar	assertions	utilizing	these	rules	classificationsconcordant	were	achieved	14/15	(93	3%)	ben/lben	and16/16	(100%)	path/lpath	consensus	an	overall	concordance	of96	8%	(30/31)	where	agreement	not	reached	a	synonymousvariant	near	splice	donor	noncanonical	sequence	which	in	silico	modelscannot	predict	native	site	applying	six	vus	five	confvariants	adding	shared	internal	laboratory	data	enabled	one	be	classifiedas	lben	two	conf	as	classified	path	lpath	this	studyhighlights	benefit	gene-specific	value	sharinginternal	our	criteriaand	expertly	reviewed	should	prove	helpful	laboratories	otherscurating
